Peptides Market

Q: Which region held the largest market share in the Peptides Market?

North America had the largest share of the global market. Read More

ID: MRFR/HC/54395-CR

189 Pages

Rahul Gotadki

June 2025

Peptides Market Research Report Information By Route Of Administration (Oral, Parenteral (Intravenous, Subcutanous, Intramuscular),And Others), By Age Group (Pediatric, And Adult), By Indication (Diabetes Mellitus, Obesity, Short Bowel Syndrome (SBS),Human Growth Hormone (HGH) Deficiency(Pediatrics, Adult) ,Hemophilia, Acromegaly, Hypoparathyroidism ,Cancer, Neurological disorders, Cardiovascular Disorders, Others), By Distribution Channel(Hospital Pharmacies ,Retail Pharmacies, Online Pharmacies) and by Region (North America, Europe, Asia-P...

Peptides Market Research Report – Forecast till 2035 Infographic

Single User

$ 4,950.0

Multiple License

$ 5,950.0

Enterprise User

$ 7,250.0

Summary Table of Contents Segmentation Infographic

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Customize Report

Certified Researchers

Peptides Market Summary

The global peptides market is projected to experience substantial growth, reaching 97.2 USD billion by 2035.

Key Market Trends & Highlights

Peptides Key Trends and Highlights

The global peptides market is valued at 43.1 USD billion in 2024.
From 2025 to 2035, the market is expected to grow at a CAGR of 7.67%.
By 2035, the market is anticipated to reach a valuation of 97.2 USD billion.
Growing adoption of peptide therapeutics due to increasing prevalence of chronic diseases is a major market driver.

Peptides Market

CAGR

7.67%

Market Size & Forecast

2024 Market Size	43.1 (USD Billion)
2035 Market Size	97.2 (USD Billion)
CAGR (2025-2035)	7.67%

Major Players

AMGEN INC., ELI LILLY AND COMPANY, PFIZER INC., SUN PHARMACEUTICAL INDUSTRIES LTD., MERCK KGAA, TAKEDA PHARMACEUTICAL COMPANY LIMITED, ASTRAZENECA, NOVARTIS AG, SANOFI, IRONWOOD PHARMACEUTICALS, INC.

Peptides Market Trends

Increasing Funding Associated With Peptide Platform And Drug

This influx of capital can also facilitate partnerships and collaborations, driving advancements in technology and improving manufacturing processes for greater efficiency and scalability. For instance,

March 2024: Grant for Prostate Cancer Therapy

Department of Urology at The University of Kansas Cancer Center has received a nearly USD 1.4 billion grant from the U.S. Department of Defense (DoD) to develop a short peptide-based therapy for prostate cancer. As prostate cancer progresses, it often develops resistance to standard treatments like androgen-deprivation therapy and androgen receptor antagonists.

This resistance presents significant challenges in effective treatment. However, recent research indicates a potential breakthrough by targeting the stability of the androgen receptor protein, a critical factor in the cancer's development and progression. The grant will support further exploration of this innovative therapeutic approach.

July 2024: CordenPharma Investment in Peptide Plants

CordenPharma (US) had made a substantial investment of nearly one billion dollars in peptide plants across the US and Europe, driven by the surging popularity of peptide-based weight-loss and antidiabetes drugs. The strong demand for glucagon-like peptide 1 (GLP-1) agonists is a primary catalyst for CordenPharma to expand its peptide services.

Additionally, the growing need for peptides in areas such as oncology and radiopharmaceuticals further underscore this investment. With part of the new funding, CordenPharma plans to add reactors for peptide synthesis at its Boulder, Colorado facility, enhancing its production capabilities.

The company is also set to establish a new facility in Europe dedicated to early-to-late-stage commercial manufacturing, positioning itself to meet the increasing global demand for peptide therapies.

The global peptides market is poised for robust growth, driven by increasing applications in therapeutics and diagnostics, alongside a rising demand for personalized medicine solutions.

U.S. National Institutes of Health

Peptides Market Drivers

Market Growth Projections

The Global Peptides Market Industry is projected to experience substantial growth, with estimates indicating a market value of 97.2 USD Billion by 2035. This anticipated growth reflects the increasing recognition of peptides in various sectors, including pharmaceuticals, cosmetics, and nutrition. The market's expansion is driven by several factors, including rising demand for therapeutic peptides, advancements in synthesis technologies, and the growing interest in personalized medicine. As the industry evolves, it is likely to witness a compound annual growth rate of 7.67% from 2025 to 2035, highlighting the dynamic nature of the Global Peptides Market Industry.

Rising Demand for Therapeutic Peptides

The Global Peptides Market Industry experiences a notable surge in demand for therapeutic peptides, driven by their efficacy in treating various diseases. Peptides are increasingly recognized for their role in drug development, particularly in oncology and metabolic disorders. For instance, the market is projected to reach 43.1 USD Billion in 2024, reflecting a growing acceptance of peptide-based therapies. This trend is further supported by advancements in peptide synthesis technologies, which enhance the production of high-purity peptides. Consequently, the therapeutic segment is anticipated to dominate the market, contributing significantly to the overall growth of the Global Peptides Market Industry.

Growing Interest in Personalized Medicine

The Global Peptides Market Industry is significantly influenced by the growing interest in personalized medicine. As healthcare shifts towards tailored treatment approaches, peptides are emerging as vital components due to their specificity and reduced side effects. Personalized peptide therapies can be designed to target individual patient profiles, enhancing treatment efficacy. This trend is particularly relevant in oncology, where targeted therapies are paramount. The increasing focus on personalized medicine is expected to drive market growth, as healthcare providers seek innovative solutions to improve patient outcomes. Consequently, the Global Peptides Market Industry is poised for substantial expansion in the coming years.

Advancements in Peptide Synthesis Technologies

Technological advancements in peptide synthesis are reshaping the Global Peptides Market Industry. Innovations such as solid-phase peptide synthesis and automated synthesizers have significantly improved the efficiency and scalability of peptide production. These advancements enable the manufacturing of complex peptides with high purity and yield, catering to the rising demand in pharmaceuticals and research. Furthermore, the integration of artificial intelligence in peptide design is streamlining the discovery process, potentially leading to the development of novel therapeutic candidates. As a result, the market is likely to benefit from enhanced production capabilities and a broader range of peptide offerings.

Expansion of Research and Development Activities

The Global Peptides Market Industry is bolstered by the expansion of research and development activities in the pharmaceutical and biotechnology sectors. Increased investment in R&D is evident as companies strive to innovate and discover new peptide-based drugs. Governments and institutions are also funding research initiatives, which fosters collaboration between academia and industry. This collaborative environment is likely to lead to the discovery of novel peptides with therapeutic applications. As a result, the market is expected to witness a compound annual growth rate of 7.67% from 2025 to 2035, indicating a robust pipeline of peptide therapeutics in development.

Increasing Applications in Cosmetics and Nutrition

The Global Peptides Market Industry is witnessing an increase in applications beyond pharmaceuticals, particularly in cosmetics and nutrition. Peptides are gaining traction in skincare products due to their ability to promote collagen production and improve skin elasticity. Additionally, the nutritional sector is exploring peptide-based supplements for their potential health benefits, such as muscle recovery and weight management. This diversification of applications is expected to contribute to market growth, as consumers increasingly seek products that leverage the benefits of peptides. The expansion into these sectors indicates a broader acceptance of peptides, further solidifying their role in the Global Peptides Market Industry.

Market Segment Insights

Global Peptides Route of Administration Insights

Based on Route of Administration, the Peptides Market has been bifurcated into Oral and Parenteral. Parenteral is further segmented into Intravenous, Subcutaneous, and Intramuscular. The parenteral segment held the largest market share in 2024, and the oral segment is the fastest-growing segment during the forecast period (2024 -2035).

The oral route has gained traction due to its non-invasive nature, making it more convenient for patients, particularly for chronic diseases requiring long-term therapy. According to the Centre for Diseases Control and Prevention in 2019, the prevalence of chronic diseases in adults was around 60% globally, and it is reportedly much higher among elderly people. It is estimated that about 70% of adults will die of one or more chronic diseases. The rising prevalence of cancer, cardiovascular disorders, diabetes, Parkinson's disease, and other conditions demands oral medications.

However, challenges such as the low bioavailability of peptides via the oral route have driven significant research into advanced formulations to improve peptide absorption. Government agencies, particularly in the US and Europe, have supported initiatives that encourage innovation in oral peptide formulations, aiming to enhance patient compliance and reduce healthcare costs. The rising focus on patient-friendly drug delivery systems and growing interest in self-administrable therapies are key drivers in this segment.

On the other hand, the parenteral route dominates the peptides market due to its higher efficacy and bioavailability. Intravenous administration is more favored for critical care treatments such as cardiovascular diseases and others requiring quick onset action. Government healthcare expenditure for critical care treatments in developed markets such as the US, Japan, and Europe for a disease like cancer has helped increase the adoption rate of IV peptide treatments.

Subcutaneous administration is highly used for chronic conditions such as diabetes and obesity with various long-acting peptide formulations that have obtained market approval. For instance, in June 2021, semaglutide (2.4 mg, Wegovy) received USFDA approval as a treatment for obesity or overweight in adults. Apart from this, the rise in chronic diseases, improvement in healthcare infrastructure in emerging markets like China and India, is thus supporting growth in the Subcutaneous segment.

Global Peptides Age Group Insights

Based on Age Group, the Peptides Market has been bifurcated into Pediatrics and Adult. The adult segment held the largest market in 2024, and the pediatric segment is the fastest growing segment during the forecast period.

In the Pediatrics segment, the incidence of pediatric diseases has been on the rise with diseases such as diabetes, growth hormone deficiencies, and rare genetic disorders. Ensuring better outcomes for the future generation around the globe has become a goal and priority among governments and healthcare organizations when it comes to advanced treatments like peptide therapy.

Pediatric preparations of peptide drugs are designed to be sensitive to the diverse metabolic and physiological needs of children and thereby increase the scope for clinical trials and investments in R&D. The incidence of pediatric diabetes is on the rise not only in developing nations but also in well-developed nations like the US and Europe, due to which there is an increased effort in developing child-friendly peptide-based treatments for glycemic control. According to global health statistics, the incidence of pediatric endocrine disorders has been gradually increasing over the last decade. This further increases the demand for innovative therapies.

The dominant chronic diseases like cardiovascular diseases and metabolic disorders with a growing prevalence have constituted an important growth driver in the Adult segment of peptide-based treatments. Peptide therapies are also increasingly trending in adults. This can be seen in the management of age-related conditions such as neurodegenerative diseases.

Moreover, the sales of peptides for anti-obesity and anti-diabetic treatments will grow with the increasing rates of obesity and diabetes in developed and developing countries. In this regard, the public, government, and health administrations have made investments in the development of medical products and been placing peptide medicine on the commercial map. Indeed, in 2020, FDA and EMA approvals for peptide drugs treating adults showed significant surge.

Global Peptides Indication Insights

Based on Indication, the Peptides Market has been segmented into Diabetes Mellitus, Obesity, Short Bowel Syndrome (SBS), Human Growth Hormone (hGH) Deficiency, Hemophilia, Acromegaly, Hypoparathyroidism, Cancer, Neurological disorders, Cardiovascular Disorders, and Others. Human Growth Hormone (hGH) Deficiency is further bifurcated into Pediatrics and Adult. The diabetes mellitus segment held the largest market in 2024, and the human growth hormone (HGH) segment is the fastest growing segment during the forecast period.

Diabetes Mellitus is one of the primary drivers for the peptide market due to the rising global incidence of diabetes. According to the International Diabetes Federation (IDF), in 2021, approximately 537 billion people worldwide were living with diabetes, and this number is expected to soar to 643 billion by 2030. Similarly, according to the American Diabetes Association, diabetes affected 38.4 billion Americans, or 11.6% of the population, in 2021. Type 1 diabetes affects around 2.0 billion Americans, including approximately 304,000 children and adolescents.

The growing adoption of peptide-based therapies, particularly GLP-1 receptor agonists such as Liraglutide and Semaglutide, is playing a critical role in improving glycemic control and reducing the risk of cardiovascular complications in diabetic patients. Governments in regions like the US, Europe, and Asia-Pacific are increasing healthcare expenditure to manage the diabetes burden, thereby promoting the use of innovative peptide therapies.

Similarly, the growing prevalence of obesity is another key factor driving the demand for peptides. According to the WHO, in 2022, one in eight individuals globally was living with obesity. Peptide-based treatments like GLP-1 analogs are gaining popularity as they aid in appetite suppression and weight loss. The increased government focus on tackling obesity-related diseases, combined with rising public health initiatives, is boosting the growth of this segment.

In the case of Short Bowel Syndrome (SBS), the increasing number of cases, especially in pediatric populations, is driving demand for peptide-based therapies that improve nutrient absorption. Teduglutide, a peptide therapy approved by the FDA, has become a major therapeutic option for SBS patients, addressing the malabsorption issues inherent to the condition. This, along with government support for orphan drugs and rare disease treatments, is expected to accelerate the adoption of peptide therapies for SBS.

Global Peptides Distribution Channel Insights

Based on Distribution Channel, the Peptides Market has been segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The hospital pharmacies segment held the largest market in 2024, and the online pharmacies segment is the fastest growing segment during the forecast period.

Due to increased prescription of peptide-based drugs in critical and complex conditions such as diabetes, and cardiovascular diseases among others, drug therapy in hospitals forms a vast market. Hospitals are centers that have the sole responsibility of carrying out peptide therapy, especially for critical care and specialized treatments. The world is witnessing an in-crease in hospital admissions with chronic diseases. With the availability of advanced peptide drugs on the hospitals, this segment is experiencing a boost in demand.

The hospitals are not only working on the infrastructure of hospitals but are also upgrading the therapeutics available to patients, which include access to peptides, further fueling the market.

Retail Pharmacies are also seeing a steady hike in the demand for peptide drugs. With more peptide-based drugs receiving approval for outpatient use, the treated patients can directly buy these drugs from retail pharmacies. Increasingly diagnosed lifestyle diseases like obesity and diabetes in the body have increased the demand for peptide therapies, many of which are now available in retail pharmacies. The convenience of accessing peptide-based drugs through a retail outlet, along with an enhancement of the pharmaceutical chain, is also a key growth driver for this segment.

Public health initiatives and insurance coverage for drugs taken for chronic diseases have cemented the retail pharmacies in the marketplace of peptides.

Get more detailed insights about Peptides Market Research Report – Forecast till 2035

Request Free Sample

Key Companies in the Peptides Market market include

Industry Developments

August 2024: Eli Lilly and Company - Zepbound (tirzepatide) Availability

In August 2024, Eli Lilly and Company has announced that Zepbound (tirzepatide) is now available for self-pay patients with an on-label prescription, greatly increasing the supply in response to high demand. The single-dose vials are offered at a discount of 50% or more compared to the list prices of other GLP-1 medications for obesity. The single-dose vials are priced at a discount of 50% or more compared to the list prices of all other GLP-1 medications for obesity.

January 2024: Takeda and Protagonist Therapeutics, Inc. - Rusfertide Agreement

In January 2024, Takeda and Protagonist Therapeutics, Inc. have signed a global license and collaboration agreement for the development and commercialization of rusfertide, an investigational injectable hepcidin mimetic peptide of the natural hormone hepcidin that was in a pivotal Phase 3 trial, VERIFY, for the treatment of Polycythemia Vera (PV).

Future Outlook

Peptides Market Future Outlook

The Global Peptides Market is projected to grow at a 7.67% CAGR from 2024 to 2035, driven by advancements in drug development, increasing healthcare expenditure, and rising demand for personalized medicine.

New opportunities lie in:

Invest in innovative peptide synthesis technologies to enhance production efficiency.
Develop targeted therapies utilizing peptides for chronic diseases and cancer treatment.
Explore partnerships with biotech firms to expand peptide applications in diagnostics.

By 2035, the Peptides Market is expected to achieve substantial growth, reflecting evolving healthcare needs and technological advancements.

Market Segmentation

Global Peptides Regional Outlook

US
Canada
Mexico

Peptides Market By Age Group Outlook (USD Billion, 2019-2035)

Pediatrics
Adult

Peptides Market By Indication Outlook (USD Billion, 2019-2035)

Pediatrics
Adult

Peptides Market By Distribution Channel Outlook (USD Billion, 2019-2035)

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Peptides Market By Route Of Administration Outlook (USD Billion, 2019-2035)

Intravenous
Subcutaneous
Intramuscular

Report Scope

Report Attribute/Metric	Details
Market Size 2024	USD 43.12 Billion
Market Size 2025	USD 45.58 Billion
Market Size 2035	USD 97.18 Billion
Compound Annual Growth Rate (CAGR)	7.11% (2025-2035)
Base Year	2024
Market Forecast Period	2025-2035
Historical Data	2019- 2024
Market Forecast Units	Value (USD Billion)
Report Coverage	Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
Segments Covered	By Route Of Administration, By Age Group, By Indication, By Distribution Channel and Region.
Geographies Covered	North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
Countries Covered	The U.S., Canada, Mexico, Germany, France, Italy, UK, Spain, China, Japan, India, UAE, South Africa, Saudi Arabia, Argentina, and Brazil.
Key Companies Profiled	AMGEN INC., ELI LILLY AND COMPANY, PFIZER INC., SUN PHARMACEUTICAL INDUSTRIES LTD., MERCK KGAA, TAKEDA PHARMACEUTICAL COMPANY LIMITED, ASTRAZENECA, NOVARTIS AG, SANOFI, IRONWOOD PHARMACEUTICALS, INC., among others.
Key Market Opportunities	· INCREASING FUNDING ASSOCIATED WITH PEPTIDE PLATFORM AND DRUG · INCORPORATION OF ARTIFICIAL INTELLIGENCE IN MANUFACTURING PEPTIDE-BASED THERAPEUTICS
Key Market Dynamics	· GROWING AWARENESS OF PEPTIDE-BASED THERAPEUTICS · GROWING ACQUISITION AND AGREEMENT ASSOCIATED WITH THE PEPTIDE PRODUCTS

FAQs

How much is the Peptides Market?

The Peptides Market size is expected to be valued at USD 97.18 Billion in 2035.

What is the growth rate of the Peptides Market?

The global market is projected to grow at a CAGR of 7.11% during the forecast period, 2024-2035.

Which region held the largest market share in the Peptides Market?

North America had the largest share of the global market.

Who are the key players in the Peptides Market?

The key players in the market are Astec Industries AMGEN INC., ELI LILLY AND COMPANY, PFIZER INC., SUN PHARMACEUTICAL INDUSTRIES LTD., MERCK KGAA, TAKEDA PHARMACEUTICAL COMPANY LIMITED, ASTRAZENECA, NOVARTIS AG, SANOFI, IRONWOOD PHARMACEUTICALS, INC., among others.

Which Indication led the Peptides Market?

The Diabetes Mellitus category dominated the market in 2024.

Which Route of Administration had the largest market share in the Peptides Market?

Parenteral segment had the largest revenue share of the global market.

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Customer Stories

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Victoria Milne Founder

Case Study

Chemicals and Materials

Global Magnesium Sulfate Market – Forecast till 2027